While proven to help, primary care clinicians have been slow to use the drugs once considered only for patients with diabetes.

Please provide your email address to receive an email when new articles are posted on . Patients who received pharmacy consultation were more likely to be prescribed an SGLT2 inhibitor. More patients ...

Use of sodium-glucose cotransporter-2 inhibitor (SGLT2) drugs should continue in patients with diabetes, in line with current recommendations, conclude the American Association of Clinical ...

A BMJ guideline put patient risk into the equation for assessing the suitability of SGLT-2 inhibitors and GLP-1 receptor agonist drugs for type 2 diabetes. Their use in type 2 diabetes was only ...

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors used to treat type 2 diabetes are associated with an 11% lower risk of autoimmune rheumatic diseases, such as rheumatoid arthritis and lupus, ...

Treating kidney disease GLP-1s show higher risk than SGLT2 inhibitors in kidney outcomes, but lower albuminuria and mortality rates.

News and commentary from the world of gastroenterology and hepatology ...

A large cohort study found three popular GLP-1-based diabetes drugs -- semaglutide, dulaglutide, and tirzepatide -- carry similar risks for serious adverse GI events, with a rate of about 12 per 1,000 ...

A UC San Francisco analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction of the patients who are recommended to take them based on new ...